Imatinib
Recurrent T Lymphoblastic Leukemia/Lymphoma
University of WashingtonSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
49 Active assets in the Recurrent T Lymphoblastic Leukemia/Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Children's Oncology Group | Phase 3 | BB |
Cyclophosphamide Children's Oncology Group | Phase 3 | BB |
Cytosin-Arabinosid Princess Maxima Center for Pediatric Oncology | Phase 3 | BB |
ETOPOSIDE Children's Cancer Group, China | Phase 3 | BB |
Daunorubicin Children's Oncology Group | Phase 3 | B |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →